'Really reassuring': Israeli study on COVID-19 vaccine finds low risk of reaction among those with history of allergies
About 98 per cent of people with a history of multiple allergies suffered no allergic reactions after receiving a Pfizer-BioNTech vaccine, according to a study conducted in Israel and published recently online in JAMA Network Open.
Of the approximately 2 per cent who did react, none required hospitalization, and symptoms cleared up with medication within a few hours.
“That's really reassuring,” said Dr. Donald Vinh, an immunologist at the MUHC, who explained the study is important because it replicates previous but smaller studies with similar results.
Another point highlighted by the study is that “even if you had a reaction to the first dose of your Pfizer vaccine, you can still go ahead and proceed with your second dose with essentially no risk of having a recurrence of that same allergic reaction,” Vinh said in an interview with CTV News, after reviewing the publication.
Vinh said this brings to the forefront what most studies have shown, “which is concern about allergies should not be a reason to avoid getting the COVID vaccines.”
SAFEGUARDS IN PLACE
To reinforce that advice, Vinh offered encouragement to those with allergies who have held off getting a vaccine thus far, adding vaccines are administered in supervised settings in Quebec.
“They have the trained personnel, the equipment, and the necessary emergency medications in case there's an allergic reaction,” Vinh said.
People are pre-screened for allergies and any contraindications before receiving the shots and are monitored for at least 15 minutes afterward.
Even a serious reaction like anaphylaxis can be treated on the spot, he says.
The Israeli study had a similar framework in place but monitored individuals deemed to be at high risk for two hours following the injections.
The authors concluded that “only patients defined as highly allergic should receive vaccination under medical supervision.”
It’s not known how many Quebecers are shying away from vaccination because of fears related to allergies to food, medications, or environmental factors.
Vinh said it doesn’t appear to be an overwhelming number of people, but is a sizable proportion nonetheless, who should be “reassured,” by this research, and get vaccinated.
ALLERGY FEARS PRESENT AN OBSTACLE
Questions about allergy risks prompted the Sheba Medical Centre in Israel to open a COVID-19 referral centre when the country first rolled out its Pfizer-BioNTech vaccination campaign eight months ago.
“Concerns regarding safety and, particularly, severe allergic reactions to this vaccine are a significant obstacle to implementation of this large immunization program,” the study's authors wrote.
Between December 2020 to February 2021, researchers assessed 8,102 participants for allergy risks according to certain criteria.
There were 429 individuals in the group considered to be at high risk for allergic reactions, which amounted to 5 per cent of the total number of participants.
Women made up the majority of the high-risk group (70.9 per cent), with 63.2 per cent of the entire group reporting prior anaphylaxis.
Following immunization with the first dose, nine women had allergic reactions within the two-hour observation period.
Six of them had minor reactions including skin flushing, tongue or uvula swelling, or a cough that diminished after treatment with an antihistamine.
Three women had anaphylactic reactions 10 to 20 minutes after getting the shot, among other symptoms.
They were treated with several medications including adrenaline and antihistamines. The symptoms resolved with 2 to 6 hours and no one required hospitalization.
When it came time for the second dose, four patients from the highly allergic group had mild allergic reactions.
CTVNews.ca Top Stories
WATCH LIVE Trudeau offering Canadians a temporary tax break on toys, takeout, snacks and more heading into holidays
Canadians will soon receive a temporary tax break on essential items, children's clothing and diapers, restaurant and pre-prepared meals and common stocking stuffers, Prime Minister Justin Trudeau announced Thursday. Trudeau also announced a new 'Working Canadians Rebate' that will send a $250 payment to 18.7 million Canadians in early spring 2025.
Ontario man agrees to remove backyard hockey rink
A Markham hockey buff who built a massive backyard ice rink without permissions or permits has reluctantly agreed to remove the sprawling surface, following a years-long dispute with the city and his neighbours.
Parole board 'working' to have Bernardo victims' families attend hearing in-person
The Parole Board of Canada says it is now working to allow victims' families to attend Paul Bernardo's parole hearing and deliver their victim impact statements in person.
Canadian painting found in barn, purchased for US$50 sells for hundreds of thousands at auction
An Emily Carr painting that sold for US$50 at an estate sale has fetched C$290,000 at a Toronto auction.
'Ding-dong-ditch' prank leads to kidnapping, assault charges for Que. couple
A Saint-Sauveur couple was back in court on Wednesday, accused of attacking a teenager over a prank.
Volcano on Iceland's Reykjanes Peninsula erupts for the 7th time in a year
A volcano in southwestern Iceland that has roared back to life after eight centuries of silence has erupted for the seventh time since December, sending molten lava flowing towards the Blue Lagoon spa, a major tourist attraction.
2 arrested during Greenpeace protest outside Stornoway residence in Ottawa
Two people have been arrested following a protest outside Stornoway, the official residence of Canada's leader of the Opposition.
1991-2024 Sea Bears player Chad Posthumus dies at 33
Sea Bears centre Chad Posthumus has died at age 33.
REVIEW 'Gladiator II' review: Come see a man fight a monkey; stay for Denzel's devious villain
CTV film critic Richard Crouse says the follow-up to Best Picture Oscar winner 'Gladiator' is long on spectacle, but short on soul.